
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma Inc. demonstrates a strong potential for growth through its innovative product candidates, particularly STRO-004, which promises enhanced clinical benefits and safety compared to existing alternatives in the antibody-drug conjugate (ADC) market. The company has showcased a solid history in designing ADCs with minimal eye toxicity and exhibited operational consistency across its pipeline, reinforcing confidence in its proprietary XpressCF platform's capacity to produce therapeutics with improved drug exposures and tolerability. Additionally, insights from key opinion leaders suggest that STRO-004’s preclinical safety metrics and unique attributes position it favorably in the competitive landscape, enhancing its likelihood of gaining market traction and addressing historical challenges in ADC treatments.
Bears say
Sutro Biopharma, Inc. faces significant challenges due to the prevailing issues related to ocular toxicity associated with antibody-drug conjugates (ADCs), which hinder physician adoption and patient agreement to treatment. The clinical concerns are compounded by the lengthy delays patients experience in obtaining specialized care for ocular toxicities, leading to frequent treatment interruptions for 15-20% of patients. Additionally, uncertainties surrounding the role of pseudokinases in cancer biology raise concerns about the effectiveness of targeting these proteins, thus contributing to the negative outlook on the company's future performance.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares